Before the discovery of VMAT2 inhibitors, managing TD primarily focused on reducing the dose of offending medication, switching to alternative medications with lower risks of TD, or discontinuing the causative medication if clinically feasible. This evidence concerns the gene SLC18A2 and thanatophoric dysplasia.